New bronchodilators in treatment of chronic obstructive pulmonary disease

Year 2016, , 23 - 25, 27.11.2016

Baran Balcan

https://doi.org/10.5472/MMJsi.2902.06

Abstract

Chronic obstructive pulmonary disease (COPD), a common

preventable and treatable disease, is characterized by persistent

airflow limitation that is usually progressive and associated with

an enhanced chronic inflammatory response in the airways and

the lung to noxious particles or gases. Clinical diagnosis of COPD

should be considered in any individual, who has dyspnea, chronic

cough, sputum production, and positive history of risk factors.

Pharmacologic therapy can reduce COPD symptoms, reduce

the frequency and severity of exacerbations, and improve health

status and exercise tolerance. After cessation of smoking and

life style modification, bronchodilator therapy is the first step in

COPD treatment. Beside commonly used bronchodilator therapy

newly developed bronchodilators started to be preferred. These

drugs consist of long-acting beta2 agonist (Indacatarol, Vilanterol,

Olodaterol, Abediterol), long acting muscarinic antagonism

(Umeclidinium), long-acting beta2 agonist with inhaled steroid

(combination of fluticasone furoate and vilanterol), long-acting

beta2 agonist with a long-acting muscarinic antagonist (Fixeddose

combination of indacaterol with glycopyrronium by means of

breezhaler device).

Keywords

Pulmonary disease, Chronic obstructive, Bronchodilator agents

References

• Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: Gold executive summary. Am J Respir Crit Care Med 2013;187:347-65.
• Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: Current burden and future projections. Eur Respir J 2006;27:397-412.